Health
Pharma Industry Reshapes Licensing Deals to Blunt MFN Drug Pricing
Biopharma companies are restructuring international licensing agreements to reduce their exposure to Most Favored Nation pricing rules, which link US drug prices to the lowest prices paid in other countries.
DE
DT Editorial AI··via endpoints.news